Research Article
Clinical Characteristics of Turkish Women with Candida krusei Vaginitis and Antifungal Susceptibility of the C. krusei Isolates
Table 4
Antifungal susceptibility of 28 vaginal Candida krusei isolates stratified according to clinical forms.
| Antifungals | Acute VVC () | Recurrent VVC () | Control () |
| Amphotericin B (g/mL) | | | | MIC range | 0.03–0.25 | 0.03–0.5 | 0.06–0.5 | MIC50 | 0.03 | 0.25 | 0.25 | MIC90 | 0.25 | 0.25 | 0.25 | , ≥2 g/mL | | | | (%) | — | — | — | 5-Flucytosine (g/mL) | | | | MIC range | 0.125–8 | 0.125–8 | 0.125–16 | MIC50 | 2 | 2 | 8 | MIC90 | 8 | 8 | 16 | , ≥32 g/mL | | | | (%) | — | — | — | Caspofungin (g/mL) | | | | MIC range | 0.03–0.06 | 0.03–0.06 | 0.03–0.06 | MIC50 | 0.03 | 0.03 | 0.03 | MIC90 | 0.06 | 0.03 | 0.06 | , ≥2 g/mL | | | | (%) | — | — | — | Fluconazole (g/mL)# | | | | MIC range | 16–128 | 16–128 | 16–128 | MIC50 | 128 | 64 | 32 | MIC90 | 128 | 128 | 128 | , ≥64 g/mL | | | | (%) | 4 | 9 | 3 | S-DD, 16–32 g/mL | | | | (%) | 3 | 4 | 5 | Itraconazole (g/mL) | | | | MIC range | 0.125–16 | 0.125–16 | 0.125–8 | MIC50 | 0.25 | 0.25 | 0.125 | MIC90 | 4 | 4 | 2 | , ≥1 g/mL
| | | | (%) | 3 | 4 | 3 | Voriconazole (g/mL) | | | | MIC range | 0.125–8 | 0.125–16 | 0.25–8 | MIC50 | 1 | 0.5 | 0.5 | MIC90 | 4 | 4 | 2 | , ≥4 g/mL | | | | (%) | 2 | 2 | 1 | Ketoconazole (g/mL) | | | | MIC range | 0.125–8 | 0.25–8 | 0.25–8 | MIC50 | 0.25 | 4 | 0.25 | MIC90 | 2 | 8 | 8 | , ≥16 g/mL | | | | (%) | — | — | — | Econazole (g/mL) | | | | MIC range | 0.5–1 | 0.125–2 | 0.5–1 | MIC50 | 1 | 1 | 1 | MIC90 | 1 | 2 | 1 | , ND | | | | (%) | — | — | — | Miconazole (g/mL) | | | | MIC range | 0.25–0.5 | 0.06–1 | 0.25–0.5 | MIC50 | 0.25 | 0.25 | 0.25 | MIC90 | 0.5 | 1 | 0.5 | , ≥4 g/mL | | | | (%) | — | — | — | Sulconazole (g/mL) | | | | MIC range | 1–4 | 0.06–4 | 1-2 | MIC50 | 2 | 1 | 1 | MIC90 | 4 | 4 | 2 | , ND | | | | (%) | — | — | — |
|
|
VVC: vulvovaginal candidiasis; : resistance; S-DD: susceptible dose dependent; ND: not determined. #All isolates were declared resistant to fluconazole.
|